Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025Blood

Impact of germline and somatic TP53 mutations on allogeneic HSCT outcomes in hematologic malignancies

View Full Paper
Ask AI
Bookmark
Share

Authors

XCXingyu CaoYZYang ZhangDLDeyan Liu

Discussion

Loading...

Member takes

Overview

Analysis reveals TP53 mutations adversely affect outcomes in hematologic malignancies after allo-HSCT, suggesting targeted approaches might improve survival.

Key Points

  • The aim is to assess the impact of germline and somatic TP53 mutations on the outcomes of allogeneic HSCT in patients with hematologic malignancies.
  • Analyzed data from 5,829 patients who underwent allo-HSCT between December 2016 and May 2024.
  • Classified patients based on TP53 mutation status: somatic, pathogenic/likely pathogenic germline, and non-pathogenic/likely benign germline.
  • Evaluated 2-year overall survival (OS), leukemia-free survival (LFS), and cumulative incidence of relapse (CIR) and non-relapse mortality (NRM).
  • Of 174 patients studied, those with TP53 mutations had lower 2-year OS and LFS compared to patients without mutations.
  • Patients in complete remission before transplant had significantly better outcomes than those with non-remission.
  • Grade II-IV acute graft-versus-host disease (aGVHD) was more frequent in patients with P/LP TP53 germline mutations.

Cite This Study

Cao et al. (2025) studied this question.

synapsesocial.com/papers/69362f744fa91c937236e2e2https://doi.org/10.1182/blood-2025-7786
View Full Paper
Ask AI
Bookmark
Share